The shift to personalized medicine is gathering momentum; over 40% of all drugs and 73% of oncology drugs in development include a biomarker. Commercializing drugs with companion diagnostics creates additional complexity, as well as new challenges and opportunities.
Are you creating the product strategy for a drug with a biomarker? Are you considering partnering with a diagnostic company? Will you be launching a therapy with a companion diagnostic in the next 24 to 48 months? This webinar provides insights on trends, key challenges, potential approaches and key learnings.